Combination products present a tremendous opportunity to improve health outcomes, because they leverage multiple disciplines. If we were, for example, to focus on drugs alone with little thought to how they might be delivered, we would be surely missing a chance to enhance safety or effectiveness. Likewise, many devices can be made more effective or safer if paired with a drug.
At the end of 2016, FDA finalized a rule covering Postmarket Safety Reporting for Combination Products that now can be found at 21 C.F.R. Subpart B.[1] A few years later, in July 2019, FDA finalized a guidance ...
Blog Editors
Recent Updates
- Health Care Without the Hospital: ChatGPT Health and Claude Go Direct to Consumers
- The HTI-5 Proposed Rules: ASTP/ONC’s Cleanup and the Hard Work that Lies Ahead
- Just Released: Telemental Health Laws – Download Our Complimentary Survey and App
- OIG Limits Sign-On Bonuses to In-Home Family Caregivers
- Governing Health AI Development and Adoption: Insights from HHS’s Recently Announced Strategy to Promote AI in Healthcare